Examining the use of GLP-1 agonists in pediatric patients with hypertension, dyslipidemia, hypertriglyceridemia, and abdominal obesity may provide insights into the potential of these drugs to mitigate cardiovascular illnesses in obese adolescents. Here, GLP1R is linked to hypertriglyceridemia.